|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 278, Issue 42, 41347-41354, October 17, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mirk/dyrk1B Is a Rho-induced Kinase Active in Skeletal Muscle Differentiation*
¶
From the
Departments of Pathology and Cell & Developmental Biology, Upstate Medical University, State University of New York, Syracuse, New York 13210
Received for publication, June 25, 2003 , and in revised form, July 30, 2003.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
The Rho family of small GTPases regulates numerous signaling pathways that control the organization of the cytoskeleton, transcription factor activity, and many aspects of the differentiation of skeletal myoblasts. We now demonstrate that the kinase Mirk (minibrain-related kinase)/dyrk1B is induced by members of the Rho-family in myoblasts and that Mirk is active in skeletal muscle differentiation. Mirk is an arginine-directed serine/threonine kinase which is expressed at elevated levels in skeletal muscle compared with other normal tissues. A Mirk promoter construct was activated when C2C12 myoblasts were switched from growth to differentiation medium and was also activated by the Rho family members RhoA, Cdc42, and to a lesser degree Rac1, but not by MyoD or Myf5. Mirk protein levels increased following transient expression of constitutively active Cdc42-QL, RhoA-QL, or Rac1-QL in C2C12 cells. High concentrations of serum mitogens down-regulated Mirk through activation of the Ras-MEK-Erk pathway. As a result, Mirk transcription was induced by the MEK1 inhibitor PD98059 and by the switch from growth to differentiation medium. Mirk was induced with similar kinetics to another Rho-induced differentiation gene, myogenin. Mirk protein levels increased 10-fold within 24–48 h after primary cultured muscle cells; C2C12 mouse myoblasts or L6 rat myoblasts were induced to differentiate. Thus Mirk was induced following the commitment stage of myogenesis. Stable overexpression of Mirk enabled myoblasts to fuse more rapidly when placed in differentiation medium. The function of Mirk in muscle differentiation was established by depletion of endogenous Mirk by small interfering RNA, which prevented myoblast fusion into myotubes and inhibited induction of markers of differentiation, including myogenin, fast twitch troponin T, and muscle myosin heavy chain. Other members of the dyrk/minibrain/HIPK family of kinases in lower organisms have been shown to regulate the transition from growth to differentiation, and Mirk is now shown to participate in skeletal muscle development.
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
The Rho family of evolutionarily conserved small GTPases regulates numerous signaling pathways that control the organization of the cytoskeleton and influence cell polarity, microtubule dynamics, membrane transport, and transcription factor activity (1). Rho family members have been implicated in many aspects of the differentiation of skeletal myoblasts. Rho-GTP levels have been observed to increase during myogenic differentiation, while inhibition of Rho blocks myogenesis (2, 3). Rho family proteins are required for the transcription of the myogenin gene and various other muscle specific genes during myogenesis including skeletal
-actin and 
-myosin heavy chain (-MHC)1 (4). Rho GTPase activity was shown to regulate an adipogenesis-myogenesis decision in vivo in response to IGF-1, using mice lacking the major Rho inhibitory protein p190-B RhoGAP (5). Murine embryonic fibroblasts lacking p190-B RhoGAP underwent the "default pathway" of myogenic differentiation in response to IGF-1 unless the Rho effector Rho-kinase was inhibited (5). Conversely, IGF-1, together with oncogenically activated RhoV14, stimulated myogenic differentiation in wild-type murine embryonic fibroblasts.
In the current study, we have established that the Mirk (minibrain-related kinase) gene (6) is induced by certain Rho family members and furthermore that Mirk functions in myogenesis. Mirk is a member of the dyrk/minibrain family of arginine-directed serine/threonine protein kinases (7–9) and is identical to Dyrk1B (10). The roles of dyrk/minibrain/Mirk homologues in yeast (Yak1) and slime mold (YakA) suggest that this group of kinases regulates the transition from growth to differentiation (11, 12). During Dictyostelium growth, YakA regulates the intervals between cell division. Following nutrient depletion, YakA mediates growth arrest and an increase in protein kinase A activity, which regulates expression of adenyl cyclase and ultimately the induction of development. We have found a similar function for Mirk in myogenesis. Mirk is dramatically up-regulated when myoblasts are induced to differentiate, while depletion of endogenous Mirk by RNAi blocks myotube formation.
Mirk/dyrk1B functions as a transcription factor activator for hepatocyte nuclear factor 1 in endodermally derived tissues (13). Mirk is likely to fulfull a similar role in muscle differentiation, although the transcription factor which Mirk activates in myotubes is not yet known. Mirk itself is activated by coexpressed MKK3 (13), a MAP kinase kinase that can also activate p38 MAP kinase (14–16). Mirk activity is controlled by p38 through direct sequestration of Mirk (17). Since p38 has also been shown to be required for terminal muscle cell differentiation (18), p38 and Mirk may mediate different steps in maturation, with p38 suppressing Mirk activity. Our data in the current study demonstrate that the serine/threonine kinase Mirk/dyrk1B is active in muscle differentiation and is induced by Rho family members and by blocking the MEK1/Erk pathway.
|
EXPERIMENTAL PROCEDURES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
Materials—Antibodies to myogenin, MyoD, troponin T,
-tubulin, and p21cip1 were from Santa Cruz Biotechnology. Rabbit polyclonal antibody to a unique sequence at the C terminus of Mirk was raised as described previously (6). The MF 20 monoclonal antibody to MHC developed by D. A. Fischman was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD, National Institutes of Health, and maintained by the University of Iowa, Department of Biological Sciences, Iowa City, IA. Polyvinylidene difluoride transfer paper Immobolin-P was purchased from Millipore. PLUS reagent and LipofectAMINE were from Invitrogen; all radioactive materials were purchased from PerkinElmer Life Sciences, ECL reagents from Amersham Biosciences, and tissue culture reagents from Mediatech (Fisher). All other reagents were from Sigma. Tissue from human skeletal muscle biopsies was kept in liquid N2 until use. The frozen tissue was ground with a mortar and pestle, suspended in boiling SDS-PAGE sample buffer, further homogenized with a Dounce homogenizer, centrifuged to remove insoluble material, and size-fractionated by SDS-PAGE. Cell Culture—C2C12 mouse myoblasts were obtained from the ATCC and L6E9 rat myoblasts were a gift of S. M. Rosenthal (University of California San Francisco). Cells were maintained in growth medium (GM; Dulbecco's modified Eagle's medium containing 20% fetal bovine serum) and switched to differentiation medium (DM; Dulbecco's modified Eagle's medium containing 2% horse serum). Primary cultures of murine myoblasts were prepared from hindlimb muscles of adult mice by enzymatic dissociation using collagenase D and dispase (Roche Applied Science). The myoblasts were maintained in dishes coated with Vitrogen collagen (Cohesion Technologies, Palo Alto, CA) in growth medium for primaries (GMP; Ham's F-10 containing 20% fetal bovine serum and 10 ng/ml basic fibroblast growth factor from Promega). For studies on differentiation, the cells were plated in GMP on dishes coated with E-C-L (entactin-collagen IV-laminin) cell attachment matrix (Upstate Biotechnology). After 24 h the GMP was replaced with differentiation medium for primaries (DMP; Dulbecco's modified Eagle's medium containing 5% horse serum). U9 colon carcinoma cells were maintained as described previously (19).
Plasmids—pHX9F (Mirk) and pHX9F (kinase inactive YF Mirk) had been previously generated (6), as were the Mirk deletion mutants.2 Mirk was excised from pG9R containing the entire coding domain of Mirk/dyrk1B (6) by EcoRI digestion and ligated into pLXSN (Clontech) and transfected into PT67 retrovirus packaging cells, and the recombinant virus was harvested from the supernatant. Stable Mirk transfectants of C2C12 cells were isolated following retroviral infection with pLXSN and isolation in G418. Constitutively active Cdc42-QL, Rac1-QL, and RhoA-QL were obtained from S. Gutkind, National Institutes of Health; MyoD was obtained from E. Olsen, University of Texas at Dallas; Myf5 was obtained from B. Winter, Universitat Braunschweig; and C3 was obtained from H. Moses, Vanderbilt Medical Center.
Small Interfering RNA (RNAi) to Mirk—A sequence within the murine Mirk coding domain, GACCTACAAGCACATCATT, was cloned into the pSilencer vector. C2C12 cells were transfected with a 10 to 1 ratio (µg/µg) of RNAi plasmid to EGFP selection plasmid in serum-free medium and then isolated by fluorescence-activated cell sorting for EGFP.
Transfection and Luciferase Assay—Cells were transfected in 12-well plates for 6 h with LipofectAmine/PLUS reagent (Invitrogen) according to the supplier's manual. Transfected cells were lysed with cell culture lysis reagent and assayed for luciferase activity (relative luciferase unit) with luciferase assay reagent (Promega) in a Turner Designs luminometer. The same lysates were diluted and assayed for -galactosidase activity to normalize for transfection efficiency. Data shown are the mean of triplicate measurements.
Mirk Promoter Constructs—Starting with a PAC clone that hybridized with Mirk cDNA, a BsrFI fragment that contained 67 bp of Mirk exon I from the transcription start site of the Mirk/dyrk1B gene (6, 10), and the 6.2-kb upstream sequence, was blunt-ended with Klenow and subcloned into the HincII site of pUC19. Deletion derivatives were generated after cutting with XbaI and unique restriction enzymes in the promoter sequence, blunt-ended, and self-ligated. The Mirk promoter constructs were excised with KpnI from pUC19 and HindIII and subcloned into a luciferase reporter pGL3-Basic vector (Promega). The 6.2-kb promoter sequence linked to the luciferase reporter was named pMp-luc. pUCMp
XE47 contains a 364-bp Eco47III-BsrFI fragment of the Mirk promoter, which includes 67 bp of Mirk exon I from the transcription start site of the Mirk/dyrk1B gene. Site-directed mutagenesis was performed with mutagenic oligonucleotides using the pGEM-11Zf(+) vector (Promega) to transform BMH 71-18 mutS competent cells, and the products were sequenced to verify the mutation.
Northern Analysis for Mirk mRNA—Total RNA was prepared by the Tri-Reagent protocol (Sigma). 20 µg of total RNA from each cell lysate was electrophoresed in a 1.2% agarose-formaldehyde gel, transferred to nylon membranes by downward capillary transfer, and UV cross-linked. The membranes were hybridized to either 32P-labeled 2.2-kb Mirk cDNA or a glyceraldehyde-3-phosphate dehydrogenase probe. Probes were labeled with 32P by random priming (Promega). The blot was hybridized overnight at 65 °C with at least 107 cpm of the labeled probe, washed at room temperature three times for 7 min with 1 x SSC, 1% SDS, washed for 20 min at 68° in 0.1 x SSC, 0.1% SDS, and autoradiographed.
Immunodetection—Following treatment as indicated and washing two times with phosphate-buffered saline, cells were lysed in boiling SDS-PAGE sample buffer (50 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol). Lysates were boiled again for 5 min and vortexed vigorously. Protein determinations were made using Coomassie Blue protein assay reagent from Pierce. Depending upon the experiment, 30–50 µg of cell lysates were blotted onto polyvinylidene difluoride membranes after separation on SDS-PAGE. The blots were blocked in 5% milk in TBST (10 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 0.1% Tween 20) for 1 h at room temperature, incubated for1hat room temperature with primary antibody in TBST buffer, 3% milk, and proteins were subsequently detected by enhanced chemiluminescence.
Band Analysis—Immunoblots were scanned using a Lacie Silver-scanner and densitometry performed using the IP Lab Gel program (Scanalytics).
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
Mirk/dyrk1B Is Found in Elevated Levels in Normal Adult Skeletal Muscle and Is Induced during Differentiation of Primary Cultured Myoblasts—Our earlier Northern analysis demonstrated that Mirk mRNA expression levels are highest in skeletal muscle and testes, with much lower expression in heart, brain, colon, lung, and other tissues (6). Serial analysis of gene expression analysis of Mirk mRNA levels confirmed that Mirk mRNA was about four times as prevalent in skeletal muscle from either young or old individuals compared with a variety of normal tissues, including kidney, brain, and breast (Fig. 1A). Consistent with the mRNA data, Mirk protein was detected by Western blotting in surgical samples of human skeletal muscle from five patients (H1–H5). Mirk encodes a protein of 629 amino acids and a smaller splice variant of 601 amino acids, which migrate at
70 and 69 kDa, respectively (6). Recently a 75-kDa form arising from alternative splicing of the N terminus was identified in skeletal muscle and in differentiated 3T3-L1 cells (21). The Mirk splice variants found in each muscle tissue exhibit approximate molecular weights of 70 and 75 kDa (Fig. 1B, arrows at left). The two smaller Mirk/dyrk1B forms were seen in C2C12 cells in growth medium, while all three splice variants were detected in C2C12 cells cultured for 3 days in differentiation medium. Therefore, the induction of Mirk during C2C12 myoblast differentiation and the maintenance of elevated levels of the larger Mirk isoforms in adult human skeletal muscle suggest that Mirk may mediate muscle maturation and function.
|
We did not wish to rely solely on immortalized cell lines to confirm that Mirk was induced during skeletal muscle differentiation. Murine muscle cells were placed into primary culture in growth medium (GMP), then induced to mature by culture in differentiation medium (DMP). As shown by Western blotting, Mirk levels increased about 10-fold after 1–2 days in DMP, with similar kinetics to myogenin, another gene known to function during skeletal muscle differentiation (Fig. 1C). Two forms of a late maturation marker, fast twitch troponin T (22), were induced with a later time course than Mirk. In contrast, elevated levels of MyoD and p21 were expressed before Mirk was induced. Therefore, Mirk induction was seen during differentiation of primary cultured muscle cells, as well as in the established C2C12 cell line, and induction of Mirk and myogenin occurred with similar kinetics.
The Rho Family of GTPases Induces Mirk Expression—The Rho GTPases RhoA, Rac1, and Cdc42 differentially regulate skeletal muscle cell differentiation. RhoA and serum response factor function together to induce MyoD (3, 4). In contrast, while expression of exogenous Rac1 and Cdc42 can activate promoter constructs of certain muscle-specific genes (4), they also activate the kinases JNK and p38MAPK, which, respectively, inhibit and enhance myogenesis (23). Precise temporal regulation of these Rho GTPases and the kinases that they activate must occur during myogenesis. We tested the ability of Rho GTPases to activate the Mirk promoter after first defining the minimal Mirk promoter. A 6.2-kb pMp-luc Mirk promoter construct was fused to a luciferase reporter gene. Assessment of the reporter activity of several deletion mutants revealed that activity was lost when the deletion creating the 111-bp construct removed the putative CAAT box. Thus the 364-bp pXE47-luc Mirk promoter construct contains the minimal promoter region (Fig. 2A). After transient transfection into C2C12 cells, this reporter construct was activated when cells were placed into differentiation medium and exhibited increased activity with time in DM (Fig. 2B). Therefore, the Mirk promoter reporter construct is activated by transcription factors active in differentiating C2C12 cells.
|
The vertebrate muscle maturation program is controlled by the myogenic basic helix-loop-helix (bHLH) transcription factor family, which acts in a sequential fashion. Two of these bHLH transcription factors, MyoD and Myf5, are expressed in proliferating undifferentiated myoblasts and upon growth factor withdrawal are activated to initiate myoblast maturation and fusion into myotubes. RhoA together with serum response factor activates MyoD (3), so we next tested the activity of Rho family members on the Mirk promoter construct in differentiating C2C12 cells. Co-expression of the Mirk reporter construct with the constitutively active constructs RhoA-QL or Cdc42-QL induced an 8-fold increase in reporter activity, while co-expression with constitutively active Rac1-QL led to a smaller 4-fold increase (Fig. 2C). Thus, each of these Rho GTPases activated the Mirk promoter construct in C2C12 cells. The activity of the Mirk promoter construct was increased more each day in DM (0–2 days) by co-transfected constitutively activated RhoA-QL (Fig. 2D). After 2 days in DM, Mirk induction by endogenous RhoA was inhibited 20% by co-transfected dominant negative RhoA-N19, and 40% by the exoenzyme C3 transferase (Fig. 2D). C3 inactivates RhoA, RhoB, and RhoC proteins but not Cdc42 or Rac. Therefore, RhoA induced Mirk expression, while dominant negative RhoA and the RhoA inhibitor C3 inhibited Mirk expression. To confirm that Rho family members induced endogenous Mirk expression, constitutively active Cdc42-QL, Rac1-QL, and RhoA-QL were transiently expressed in C2C12 cells. Even though the transfection efficiencies were on average about 30%, an increase in Mirk protein over control levels was seen after 2 days of expression in DM. Compared with cells transfected with vector DNA, the Mirk to tubulin ratio increased about 1.7–2.3-fold in cells expressing activated Cdc42, Rac1, or RhoA (Fig. 2E), which translates into 6-fold increases when the efficiency of transfection is factored in. Transient expression of the Rho inhibitor C3 transferase inhibited endogenous Mirk expression (Western blotting data not shown). Thus, the Rho family members RhoA, Cdc42, and to a lesser extent Rac1, induced Mirk during C2C12 cell maturation.
Muscle-restricted basic helix-loop-helix transcription factors such as MyoD form heterodimers with other ubiquitous helix-loop-helix factors and bind to DNA elements called E boxes, which are found in the promoter regions of genes expressed in muscle. Two putative E boxes (CACGTG) were found in the pXE47 Mirk promoter construct at bp +12 (E1) and bp –245 (E2) from the Mirk/dyrk1B start site. Mutation of E1 did not alter basal transcription activity (data not shown), whereas mutation of E2 alone or both E2 and E1 resulted in a 3–4-fold decrease in basal transcription of the pXE47 Mirk promoter after 1–2 days in DM (Fig. 2B). Therefore, the Mirk promoter reporter construct is activated by transcription factors active in differentiating C2C12 cells, and moreover, mutation of the E2 E box blocks this response.
Since putative E boxes were present in the mirk promoter, we next tested transcription factors that might bind to these promoter elements. MyoD binds to an E box element in the myogenin promoter and induces its transcription (24). However, co-transfection with expression plasmids for either MyoD, Myf5, or the E box-binding protein E47 (25). had no effect on Mirk promoter construct activity (Fig. 2C). Co-expression of MyoD and E47 were likewise ineffective (not shown).
Mirk Expression Increased following Inhibition of MEK—We next considered the possibility that, in addition to up-regulation by Rho-mediated differentiation signals, Mirk transcription might be blocked by growth signals. Growth medium contains high levels of serum mitogens including IGFs, which activate the Ras-MEK-Erk system leading to cell proliferation. Switching colon carcinoma cells to serum-free medium had caused a marked increase in Mirk protein levels in earlier studies (6). Myoblasts responded in a similar fashion. Mirk protein levels increased 10-fold (Fig. 1, B and C), and the Mirk promoter construct (Fig. 2) was activated when myoblasts were transferred from high serum GM to low serum DM. While Erks can transactivate several nuclear transcription factors by phosphorylation, there are also a number of examples of Erk-mediated transcriptional down-regulation (26).
Because of these observations, the hypothesis that the MEK1-Erk pathway could inhibit Mirk transcription was tested. The Mirk minimal promoter construct pXE47-luc was activated 6-fold when C2C12 cells were treated with the MEK1 inhibitor PD98059 (Fig. 3A). A similar 6-fold activation of the E box mutant promoter was induced by PD98059 treatment, confirming that this transcriptional down-regulation was not mediated through E box elements. The MEK1 signaling pathway also blocked Mirk transcription in colon carcinoma cells, showing the generality of this response. Both the Mirk minimal promoter and the longer 6.2-kb putative promoter construct were activated by treatment of U9 colon carcinoma cells with increasing concentrations of the MEK1 inhibitor (Fig. 3B). Northern analysis confirmed the reporter assay findings. Treatment with the MEK1/2 inhibitor PD98059 increased Mirk mRNA levels 6-fold (Fig. 3, C and D, upper panel), and a parallel increase in Mirk protein level was observed (Fig. 3, C and D, lower panel). The induction of Mirk mRNA by serum-free culture was increased by concurrent treatment with cyclo-heximide to block protein translation (data not shown). Therefore, Mirk expression was negatively controlled on the transcriptional level by the Ras-Erk pathway, and protein synthesis was required to block Mirk transcription. Erk activation temporally preceded Mirk down-regulation in U9 colon carcinoma cells deprived of serum for 16 h, then released into medium containing fetal bovine serum. Serum caused a slow onset of Erk activation 3–6 h after addition, which persisted for several hours in these colon carcinoma cells, leading to a decrease in Mirk protein levels after 21–24 h (Fig. 3R). These data together show that blocking the MEK-Erk pathway increases Mirk abundance by up-regulating Mirk transcription.
|
Time Course of Mirk Induction during Myoblast Differentiation—The time course for Mirk induction in two models of myoblast differentiation, rat L6E9 cells and mouse C2C12 cells, was determined as a first step in studying the biological effects of up-regulating or down-regulating Mirk levels. Cell lysates were examined for expression of Mirk and other markers of muscle cell differentiation by Western blotting for 0–4 days after switching the cells from growth medium to differentiation medium. Mirk levels were very low in growth medium, but increased 100-fold over 4 days in DM, with a large increase seen after 1 day (Fig. 4). In both cell types myogenin was rapidly induced after 1 day in DM, while both muscle MHC and fast twitch troponin T were induced after 2 days in DM. In contrast to MHC and troponin T, the levels of which were very low or undetectable in growth medium, levels of the Cdk inhibitor p21 were already elevated when cells were switched to DM and continued to rise about 2–3-fold. Therefore, in both myoblast cell types, Mirk has a similar time course for appearance as myogenin. Mirk appears before the induction of contractile protein genes like MHC and troponin T (4), and Mirk is induced later than the MyoD-induced p21 (27–29). This pattern is very similar to that seen in primary cultured muscle cells (Fig. 1C). The vertebrate muscle maturation program is controlled by the myogenic bHLH transcription factor family, which acts in a sequential fashion. Two of these bHLH transcription factors, MyoD and Myf5, are expressed in proliferating undifferentiated myoblasts and upon growth factor withdrawal are activated to initiate myoblast maturation and fusion into myotubes. Myogenin controls the differentiation process and functions later than MyoD and Myf5. The time course analysis indicates that Mirk, like myogenin, mediates muscle differentiation, not commitment to this lineage.
|
Stable Overexpression of Mirk—Multiple experiments demonstrated that stable C2C12 Mirk transfectant cells fused more rapidly when placed in DM (Fig. 5A). Analysis by Western blotting demonstrated that more myogenin was induced at each time point up to 3 days in DM, when Mirk transfectants were compared with control transfectants (Fig. 5B). For example, on day 2, 25% more myogenin was seen in mirk transfectant cultures (p < 0.05, Student's t test). Thus overexpression of Mirk enhanced the skeletal muscle differentiation program.
|
Mirk Function in Muscle Differentiation Shown by RNAi—To confirm the role of Mirk in muscle development, endogenous Mirk levels were depleted with RNAi directed to a region of the mouse Mirk coding sequence. Initially three sequences within the Mirk coding domain were targeted (data not shown). The sequence Si1 was most effective so it was used for all subsequent experiments. C2C12 cells were co-transfected with either RNAi to Mirk or vector control DNA together with an expression plasmid for GFP. The transfected cultures were sorted for the positive transfectants by the presence of GFP and then placed in growth medium for 1 day, then switched to DM. Cell lysates were analyzed after 1 and 2 days in DM by Western blotting, with blotting and transfer controlled by measurement of tubulin. Mirk levels doubled in the vector control cultures between 1–2 days in DM, while parallel cultures treated with RNAi expressed 6% as much Mirk after 1 day and 25% as much Mirk after 2 days (Fig. 6A). The decrease in RNAi effect was due to loss of Mirk RNAi containing cells.3 Levels of myogenin and muscle MHC were very low to undetectable after 1 day in DM but increased substantially after 2 days of differentiation. However, RNAi to Mirk limited these increases to 25% of vector control levels. A smaller 20% decrease in p21 protein levels was seen in repeated experiments, but no decrease in the phosphorylation of pRb at Thr821 could be detected (data not shown).
|
Multiple RNAi experiments were performed without cell sorting and confirmed that decreases in myogenin, MHC, and to a lesser degree p21, occurred following depletion of endogenous Mirk with RNAi (data not shown). Another component of the skeletal muscle differentiation program is fast twitch troponin T. The large increases in fast twitch troponin T isoforms seen after 2 and 3 days of DM treatment were reduced by half after endogenous Mirk levels were decreased by RNAi (Fig. 6B). No decreases in MyoD were observed in multiple experiments. We conclude that depletion of endogenous Mirk by RNAi treatment prevented myoblast differentiation by blocking the induction of several muscle-specific proteins, in particular myogenin, but not MyoD. Thus Mirk must function following the commitment stage of myogenesis when MyoD is induced but prior to the induction of myogenin.
The biochemical analysis of myoblast differentiation was extended by visual examination. C2C12 cells were co-transfected with RNAi to Mirk or vector DNA along with an expression plasmid for DsRed and switched to DM. After 1 day in DM, cells with the DsRed marker were seen throughout both cultures and no myoblast fusion was seen in phase photomicrographs of the same fields (Fig. 7). However, by 5 days in DM numerous myotubes, which expressed DsRed in the vector control cultures, were observed. In contrast, the DsRed-expressing Mirk RNAi-transfected cells remained predominantly unfused single cells, with a rare small myotube. Nontransfected cells in the same culture formed normal-appearing myotubes (see phase contrast photomicrograph), demonstrating that cells in which Mirk levels were unperturbed retained the ability to undergo normal maturation, even in the presence of nonfusing cells with low Mirk levels. However, in multiple experiments, the largest myotubes were found in the control cultures. This is reasonable because in the Mirk RNAi-transfected cultures the percentage of adjacent cells capable of fusing was decreased. Cultures examined after 3 and 4 days in DM showed the same inhibition of myoblast fusion (data not shown). These biochemical and morphological studies confirm that the RhoA-induced protein kinase Mirk plays a necessary role in muscle development in these cell line models.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
Muscle cell differentiation is mediated by muscle regulatory factors (MRFs) belonging to the basic helix-loop-helix protein family, including MyoD, Myf5, myogenin, and MRF4 (30). Only MyoD and Myf5 are expressed in dividing myoblasts, indicating that they orchestrate early steps in muscle determination. Myogenin and MRF4 are not expressed in dividing myoblasts, but their expression is induced during terminal differentiation of myotubes (reviewed in Ref. 30). The Rho family of small GTPases plays a role both in muscle determination and in later steps of muscle maturation. RhoA, together with serum response factor is required for the expression of MyoD, but the related molecules, Rac or Cdc42, cannot take the place of RhoA (3). Inhibition of RhoA has been shown to block induction of myogenin, MRF4, and muscle-specific contractile proteins, while constitutively activated forms of Rho family proteins stimulated their transcription (4). In the current study we have identified the serine/threonine kinase Mirk/dyrk1B as another RhoA-induced gene involved in muscle cell differentiation. Mirk must function following the commitment stage of myogenesis when MyoD is induced but prior to the induction of myogenin.
Induction of Mirk transcription also requires a block, or at least a dimunition, of the MEK-Erk pathway. In myoblast differentiation, this block is provided by the switch from medium containing high levels of serum growth factors, to low serum or serum-free culture conditions. Mirk transcription can also be induced by treatment of C2C12 cells with the MEK1 inhibitor PD98059, which is effective in inducing Mirk even in serum containing growth medium (Fig. 3). Therefore, Mirk induction requires active Rho proteins but also inhibition of the MEK1-Erk signaling pathway.
Mirk is expressed at much higher levels in skeletal muscle and testes than in other tissues (6). Mirk is shown in this report to be expressed in every skeletal muscle biopsy examined (five of five) and to be induced in myoblasts placed in differentiation-inducing medium, including primary cultured muscle cells and two myoblast cell lines. Mirk was shown to function in muscle cell differentiation. Blocking Mirk expression with RNAi blocked myoblast fusion and decreased the expression of myogenin and the muscle-specific contractile proteins MHC and fast twitch troponin T. Mirk may act as a transcriptional activator during myoblast differentiation. Mirk has been shown to function, in a kinase-dependent manner, as a co-activator of the transcription factor HNF1 (hepatocyte nuclear factor 1) (13). Mirk binds to HNF1 through its co-factor, DCoH (dimerization co-factor of HNF1). DCoH binds as a dimer to the unstable HNF1 dimer, thus enabling effective binding of the tetrameric complex to DNA (31). HNF1 is ubiquitous in intestinal epithelium as well as epithelial cells in liver, pancreas, and other gastrointestinal tissues. The co-factor for Mirk binding to HNF1, DCoH (31), is found exclusively in colon carcinoma tissue, not normal colon epithelium (32), and Mirk is expressed in every colon carcinoma cell line examined (6). Therefore, Mirk must interact with the DCoH/HNF1 heterodimer in vivo in colon carcinomas to mediate transcription. This model for transcriptional activation by Mirk may extend to muscle tissue. Since HNF1 is not expressed in muscle cells, Mirk must activate another transcription factor. A novel member of the DCoH family, DCoHm, was cloned from a skeletal muscle cell library by our group as a Mirk-binding protein in yeast two-hybrid analysis (13). Perhaps DCoHm acts as a dimerization co-factor and stabilizer for a myocyte transcription factor.
Mirk is activated in vivo by MKK3 (13), an activator of p38 MAPK. Functional p38 MAPK has been recently shown to be required for terminal muscle cell differentation, as C2C12 cells expressing DN MKK3 failed to fuse into myotubes (18). Blocking MKK3 activity with a dominant negative construct decreased expression of MyoD and myogenin and also blocked expression of the late differentiation markers troponin T and MHC and the Cdk inhibitor, p21. Perhaps some of the effects of DN MKK3 in these studies were due in part to decreased activation of Mirk. Mirk and p38 compete for association with MKK3, and Mirk was shown to be sequestered by p38 in vivo (17). Since both p38 and Mirk play roles in myoblast differentiation, they may interact functionally.
The data presented in this study demonstrate that the serine/threonine kinase Mirk/dyrk1B is another RhoA-induced gene which is active in myogenesis. Functional deletion of Mirk by small interfering RNA prevented most myotube formation. Time course studies on primary cultured muscle cells, C2C12 murine myoblasts and rat L6E9 myoblasts, showed that Mirk functions following the commitment stage of myogenesis when MyoD is induced but prior to the induction of myogenin. Mirk is activated by the MAP kinase kinase MKK3, which activates p38MAPK (13), in a stress response pathway. The function of Mirk is blocked by p38MAPK isoforms , but not isoforms 
/
, which sequester Mirk and prevents its activation by MKK3 (17). This unusual kinase to kinase interaction suggests that Mirk and p38 (18) mediate opposite functions in myogenesis or that the activity of Mirk is temporally regulated by p38. Mirk is a member of the multigene minibrain/dyrk family. The related kinase, Yak1, acts as a growth attenuator in response to stresses and nutrient conditions in yeast (20). Another Mirk-related kinase, YakA, regulates stress responses in Dictyostelium discoideum in response to nutrient starvation (12). Mirk induction in myoblasts in response to growth factor deprivation, as described in the current study, is an interesting parallel.
|
FOOTNOTES |
|---|
* This work was supported by Public Health Service Award RO1 CA67405 (to E. F.) and American Heart Association, New York State Affliliate Award 0256199T (to M. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom all correspondence should be addressed at: Upstate Medical University, Pathology Dept., 2303 Weiskotten Hall, 750 East Adams St., Syracuse, NY 13210. Tel.: 315-464-7138; Fax: 315-464-8419; E-mail: friedmae{at}mail.upstate.edu.
1 The abbreviations used are: MHC, myosin heavy chain; IGF, insulin-like growth factor; Mirk, minibrain-related kinase; MAP, mitogen-activated protein; MAPK, MAP kinase; RNAi, small interfering RNA; GFP, green fluorescent protein; EGFP, enhanced GFP; bHLH, basic helix-loop-helix; MRF, muscle regulatory factor; HNF1, hepatocyte nuclear factor 1; DCoH, dimerization co-factor of HNF1.
2 X. Deng, S. Shah, S. Mercer, and E. Friedman, submitted for publication.
|
ACKNOWLEDGMENTS |
|---|
We thank Stephen E. Mercer for helpful suggestions and for careful reading of the text and Drs. Zhiwei Lai and Nick Gonchoroff for assistance with cell sorting. We thank Dr. Grace Pavlath for providing training in the primary muscle culture system and Dr. Anna-Luise Katzenstein, Pathology Department, for specimens of normal muscle tissue.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
- Etienne-Manneville, S., and Hall, A. (2002) Nature 420, 629–635[CrossRef][Medline] [Order article via Infotrieve]
- Charrasse, S., Meriane, M., Comunale, F., Blangy, A., and Gauthier-Rouviere, C. (2002) J. Cell Biol. 158, 953–965
[Abstract/Free Full Text] - Carnac, G., Primig, M., Kitzmann, M., Chafey, P., Tuil, D., Lamb, N., and Fernandez, A. (1998) Mol. Biol. Cell. 9, 1891–1902
[Abstract/Free Full Text] - Takano, H., Komuro, I., Oka, T., Shiojima, I., Hiroi, Y., Mizuno, T., and Yazaki, Y. (1998) Mol. Cell. Biol. 18, 1580–1589
[Abstract/Free Full Text] - Sordella, R., Jiang, W., Chen, G., Curto, M., and Settleman, J. (2003) Cell 113, 147–158[CrossRef][Medline] [Order article via Infotrieve]
- Lee, K., Deng, X., and Friedman, E. (2000) Cancer Res. 60, 3631–3637
[Abstract/Free Full Text] - Kentrup, H., Becker, W., Heukelbach, J., Wilmes, A., Schurman, A., Huppertz, C., Kainulainen, H., and Joost, H.-G. (1996) J. Biol. Chem. 271, 3488–3495
[Abstract/Free Full Text] - Becker, W., Weber, Y., Wetzel, K., Eirmbter, K., Tejedor, F., and Joost, H.-G. (1998) J. Biol. Chem. 273, 25893–25902
[Abstract/Free Full Text] - Himpel, S., Tegge, W., Frank, R., Leder, S., Joost, H., and Becker, W. (2000) J. Biol. Chem. 275, 2431–2438
[Abstract/Free Full Text] - Leder, S., Weber, Y., Altafaj, X., Estivill, X., Joost, H.-G., and Becker, W. (1999) Biochem. Biophys. Res. Commun. 254, 474–479[CrossRef][Medline] [Order article via Infotrieve]
- Moriya, H., Shimizu-Yoshida, Y., Omori, A., Iwashita, S., Katoh, M., and Sakai, A. (2001) Genes Dev. 150, 1217–1228
- Taminato, A., Bagattini, R., Gorjao, R., Chen, G., Kuspa, A., and Souza, G. M. (2002) Mol. Biol. Cell. 13, 2266–2275
[Abstract/Free Full Text] - Lim, S., Jin, K., and Friedman, E. (2002) J. Biol. Chem. 277, 25040–25046
[Abstract/Free Full Text] - Lin, A., Minden, A., Martinetto, H., Claret, F.-X., Lange-Carter, C., Mercurio, F., Johnson, G., and Karin, M. (1995) Science 268, 286–290
[Abstract/Free Full Text] - Cuenda, A., Alonso, G., Morrice, N., Jones, M., Meier, R., Cohen, P., and Nebreda, A. (1996) EMBO J. 15, 4156–4164[Medline] [Order article via Infotrieve]
- Derijard, B., Raingeaud, J., Barrett, T., Wu, I., Han, J., Ulevitch, R., and Davis, R. (1995) Science 267, 682–685
[Abstract/Free Full Text] - Lim, S., Zou, Y., and Friedman, E. (2002) J. Biol. Chem. 277, 49438–49445
[Abstract/Free Full Text] - Cabane, C., Englaro, W., Yeow, K., Ragno, M., and Derijard, B. (2003) Am. J. Physiol. 284, C658–C666
- Yan, Z., Kim, G.-Y., Deng, X., and Friedman, E. (2002) J. Biol. Chem. 277, 9870–9879
[Abstract/Free Full Text] - Garrett, S., Menold, M., and Broach, J. (1991) Mol. Cell. Biol. 11, 4045–4052
[Abstract/Free Full Text] - Leder, S., Czajkowska, H., Maenz, B., de Graaf, K., Barthel, A., Joost, H.-G., and Becker, W. (2003) Biochem. J. 372, 881–888[CrossRef][Medline] [Order article via Infotrieve]
- Mullen, A., and Barton, P. (2000) Gene (Amst.) 242, 313–320[CrossRef][Medline] [Order article via Infotrieve]
- Meriane, M., Roux, P., Primig, M., Fort, P., and Gauthier-Rouviere, C. (2000) Mol. Biol. Cell. 11, 2513–2528
[Abstract/Free Full Text] - Edmondson, D. G., Cheng, C. T., Cserjesi, P., Chakraborty, T., and Olson, E. N. (1992) Mol. Cell. Biol. 12, 3665–3677
[Abstract/Free Full Text] - Murre, C., McCaw, P., and Baltimore, D. (1989) Cell 56, 777–783[CrossRef][Medline] [Order article via Infotrieve]
- Neufeld, B., Grosse-Wilde, A., Hoffmeyer, A., Jordan, B., Chen, P., Dinev, D., Ludwig, S., and Rapp, U. (2000) J. Biol. Chem. 275, 20239–20242
[Abstract/Free Full Text] - Guo, K., Wang, J., Andres, V., Smith, R., and Walsh, K. (1995) Mol. Cell. Biol. 15, 3823–3829[Abstract]
- Halevy, O., Novitch, B., Spicer, D., Skapek, S., Rhee, J., Hannon, G., Beach, D., and Lassar, A. (1995) Science 267, 1018–1021
[Abstract/Free Full Text] - Parker, S., Eichele, G., Zhang, P., Rawls, A., Sands, A., Bradley, A., Olson, E., Harper, J., and Elledge, S. (1995) Science 267, 1024–1027
[Abstract/Free Full Text] - Rudnicki, M., and Jaenisch, R. (1995) BioEssays 17, 203–209[CrossRef][Medline] [Order article via Infotrieve]
- Rhee, K., Steir, G., Becker, P., Suck, D., and Sandaltzopoulos, R. (1997) J. Mol. Biol. 265, 20–29[CrossRef][Medline] [Order article via Infotrieve]
- Eskinazi, R., Thony, B., Svoboda, M., Robberecht, P., Dassesse, D., Heizmann, C., Van Laethem, J.-L., and Resibois, A. (1999) Am. J. Pathology. 155, 1105–1113
[Abstract/Free Full Text]
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Deng, D. Z. Ewton, and E. Friedman Mirk/Dyrk1B Maintains the Viability of Quiescent Pancreatic Cancer Cells by Reducing Levels of Reactive Oxygen Species Cancer Res., April 15, 2009; 69(8): 3317 - 3324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Craft, D. M. Krisky, J. B. Wechuck, E. K. Lobenhofer, Y. Jiang, D. P. Wolfe, and J. C. Glorioso Herpes Simplex Virus-Mediated Expression of Pax3 and MyoD in Embryoid Bodies Results in Lineage-Related Alterations in Gene Expression Profiles Stem Cells, December 1, 2008; 26(12): 3119 - 3129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Koyama, Y. Nakaoka, Y. Fujio, H. Hirota, K. Nishida, S. Sugiyama, K. Okamoto, K. Yamauchi-Takihara, M. Yoshimura, S. Mochizuki, et al. Interaction of Scaffolding Adaptor Protein Gab1 with Tyrosine Phosphatase SHP2 Negatively Regulates IGF-I-dependent Myogenic Differentiation via the ERK1/2 Signaling Pathway J. Biol. Chem., August 29, 2008; 283(35): 24234 - 24244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Jin, S. Park, D. Z. Ewton, and E. Friedman The Survival Kinase Mirk/Dyrk1B Is a Downstream Effector of Oncogenic K-ras in Pancreatic Cancer Cancer Res., August 1, 2007; 67(15): 7247 - 7255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. Petricoin III, V. Espina, R. P. Araujo, B. Midura, C. Yeung, X. Wan, G. S. Eichler, D. J. Johann Jr., S. Qualman, M. Tsokos, et al. Phosphoprotein Pathway Mapping: Akt/Mammalian Target of Rapamycin Activation Is Negatively Associated with Childhood Rhabdomyosarcoma Survival Cancer Res., April 1, 2007; 67(7): 3431 - 3440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-C. Lan, H.-J. Li, G. Lin, P.-Y. Lai, and B.-c. Chung Cyclic AMP Stimulates SF-1-Dependent CYP11A1 Expression through Homeodomain-Interacting Protein Kinase 3-Mediated Jun N-Terminal Kinase and c-Jun Phosphorylation Mol. Cell. Biol., March 15, 2007; 27(6): 2027 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Puente, S. Voisin, R. E. C. Lee, and L. A. Megeney Reconstructing the Regulatory Kinase Pathways of Myogenesis from Phosphopeptide Data Mol. Cell. Proteomics, December 1, 2006; 5(12): 2244 - 2251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Omidvar, L. Pearn, A. K. Burnett, and R. L. Darley Ral Is both Necessary and Sufficient for the Inhibition of Myeloid Differentiation Mediated by Ras Mol. Cell. Biol., May 15, 2006; 26(10): 3966 - 3975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Mercer, D. Z. Ewton, S. Shah, A. Naqvi, and E. Friedman Mirk/Dyrk1b mediates cell survival in rhabdomyosarcomas. Cancer Res., May 15, 2006; 66(10): 5143 - 5150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Deng, D. Z. Ewton, S. Li, A. Naqvi, S. E. Mercer, S. Landas, and E. Friedman The Kinase Mirk/Dyrk1B Mediates Cell Survival in Pancreatic Ductal Adenocarcinoma. Cancer Res., April 15, 2006; 66(8): 4149 - 4158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Jin, S. Lim, S. E. Mercer, and E. Friedman The Survival Kinase Mirk/dyrk1B Is Activated through Rac1-MKK3 Signaling J. Biol. Chem., December 23, 2005; 280(51): 42097 - 42105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Mercer, D. Z. Ewton, X. Deng, S. Lim, T. R. Mazur, and E. Friedman Mirk/Dyrk1B Mediates Survival during the Differentiation of C2C12 Myoblasts J. Biol. Chem., July 8, 2005; 280(27): 25788 - 25801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Deng, D. Z. Ewton, S. E. Mercer, and E. Friedman Mirk/dyrk1B Decreases the Nuclear Accumulation of Class II Histone Deacetylases during Skeletal Muscle Differentiation J. Biol. Chem., February 11, 2005; 280(6): 4894 - 4905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-H. Chen, R. Luche, B. Wei, and N. K. Tonks Characterization of Two Distinct Dual Specificity Phosphatases Encoded in Alternative Open Reading Frames of a Single Gene Located on Human Chromosome 10q22.2 J. Biol. Chem., October 1, 2004; 279(40): 41404 - 41413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zou, D. Z. Ewton, X. Deng, S. E. Mercer, and E. Friedman Mirk/dyrk1B Kinase Destabilizes Cyclin D1 by Phosphorylation at Threonine 288 J. Biol. Chem., June 25, 2004; 279(26): 27790 - 27798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Deng, S. E. Mercer, S. Shah, D. Z. Ewton, and E. Friedman The Cyclin-dependent Kinase Inhibitor p27Kip1 Is Stabilized in G0 by Mirk/dyrk1B Kinase J. Biol. Chem., May 21, 2004; 279(21): 22498 - 22504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zou, S. Lim, K. Lee, X. Deng, and E. Friedman Serine/Threonine Kinase Mirk/Dyrk1B Is an Inhibitor of Epithelial Cell Migration and Is Negatively Regulated by the Met Adaptor Ran-binding Protein M J. Biol. Chem., December 5, 2003; 278(49): 49573 - 49581. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |